Filing Flows › Dianthus Therapeutics (DNTH) › Q1 2025
Dianthus Therapeutics (DNTH) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Dianthus Therapeutics (DNTH) reported revenue of $1.2M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -12% from the quarter before.
Dianthus Therapeutics, Q1 2025: revenue $1.2M (+33% year over year), net loss $29.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -12% | +33% |
| Operating profit | −$33.2M | — | — |
| Net earnings | −$29.5M | — | — |
| Operating cash flow | −$27.6M | — | — |
What changed
Revenue was $1.2M in Q1 2025, up 33% year over year and down 12% from the previous quarter.
Operating costs exceeded revenue by $33.2M, an operating margin of -2852.7%. Total costs grew 83% against revenue growth of 33%. The fastest-growing cost line was Research & development (+106%). The quarter ended with a net loss of $29.5M, wider than the previous quarter's $28.4M loss.
Operating cash flow was −$27.6M. Non-cash charges added back $27K of depreciation and $5.3M of share-based compensation. Working capital and other items used $3.5M. Capital expenditures of $24K exceeded it, leaving free cash flow of −$27.7M.
Questions
What was Dianthus Therapeutics' revenue in the first quarter 2025?
Dianthus Therapeutics (DNTH) reported revenue of $1.2M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -12% from the quarter before.